SCHEMBL30775283

SCHEMBL30775283

O=C1NCc2c(C#Cc3ccccc3)cccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.54
CDK5 Q00535 2/20 0.50
DYRK1A Q13627 2/20 0.50
CLK4 Q9HAZ1 2/20 0.50
PIM1 P11309 1/20 0.50
CSNK1A1 P48729 1/20 0.50
ROCK1 Q13464 1/20 0.50
LRRK2 Q5S007 1/20 0.50
DYRK1B Q9Y463 1/20 0.50
LTK P29376 1/20 0.44
MST1R Q04912 1/20 0.44
KDR P35968 2/20 0.44
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
PARP10 Q53GL7 1/20 0.43
PARP11 Q9NR21 1/20 0.43
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1927437 0.82 GRM5 (0.50) GRM5PARP10PARP11
SCHEMBL2020958 0.78 CDK5 (0.58) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL6200526 0.77 GRM5 (0.50) GRM5CA12CA9PARP10PARP11
SCHEMBL29753592 0.75 CDK5 (0.46) GRM5CDK5DYRK1ACLK4PIM1
SCHEMBL30331758 0.73 PARP10 (0.69) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL3448100 0.71 GRM5 (0.54) GRM5CA12CA9KDM4EMEN1
SCHEMBL505049 0.70 GRM5 (1.00) GRM5CLK4DYRK1BCA12CA9
SCHEMBL5951796 0.70 ACHE (0.54) GRM5CA12CA9KDM4EMEN1
SCHEMBL1666085 0.69 APP (0.63) GRM5CA12CA9KDM4EMEN1
SCHEMBL31441037 0.69 PNMT (0.45) GRM5KDRCA12CA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR GRM5 1676/4885CDK5 1211/4885DYRK1A 4802/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR GRM5 1676/4885CDK5 1211/4885DYRK1A 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.